An interventional study of RhinAer in Migraine Headache, sponsored by Aerin Medical. Completed at 3 sites in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Aerin Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 697 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 697 studies in Migraine Disorders with a site in United States, this one is the 390th largest by enrollment of the 610 interventional ones that give a count, is one of 39 that started in 2023, is one of 204 with no phase, and was the 697th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →93 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 22 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
697 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 39 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 610 interventional studies, 195 across the 84 observational. Of the 527 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 697 have an industry lead sponsor. The 10 most frequent:
Aerin Medical is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Aerin Medical has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 697 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of posterior nasal nerve (PNN) neurolysis on the migraine symptoms of patients diagnosed with midfacial migraine headaches, including the frequency and intensity of migraine headache episodes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
response to a topical PNN block
Exclusion Criteria:
Device: RhinAer
Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
Change from baseline in Mid-facial Migraine Headache Days at 3 months
Assess the treatment effect of PNN neurolysis using the RhinAer procedure for treatment of midfacial migraine headaches at 3 months. This primary outcome measures the change in mid-facial migraine headache days at baseline versus 3 months post-procedure.
Time frame: Baseline (pre-procedure) and 3 months post-procedure
Change from baseline in Mid-facial Migraine Headache Days at 6 months
Assess the treatment effect of PNN neurolysis using the RhinAer procedure for treatment of midfacial migraine headaches at 6 months. This secondary outcome measures the change in mid-facial migraine headache days at baseline versus 6 months post-procedure.
Time frame: Baseline (pre-procedure) and 6 months post-procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Nov 2025, 32 months.
Of 49 industry-sponsored interventional studies with no phase under Migraine Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 32 months is above that.
Counting every sponsor, half of 358 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aerin Medical